Publication details

Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity

Investor logo
Authors

NĚMEC Václav KHIRSARIYA PrashantKumar JANOVSKÁ Pavlína MARTÍN MOYANO Paula MAIER Lukáš PROCHÁZKOVÁ Petra KEBKOVÁ Pavlína GYBEĽ Tomáš BERGER Benedict-Tilman CHAIKUAD Apirat REINECKE Maria KUSTER Bernhard KNAPP Stefan BRYJA Vítězslav PARUCH Kamil

Year of publication 2023
Type Article in Periodical
Magazine / Source Angewandte Chemie International Edition
MU Faculty or unit

Faculty of Science

Citation
Web https://doi.org/10.1002/anie.202217532
Doi http://dx.doi.org/10.1002/anie.202217532
Keywords CK1; Chemical Probe; Inhibitor; Isoform Selectivity; Wnt Pathway
Description Casein kinases 1 (CK1) are key signaling molecules that have emerged recently as attractive therapeutic targets in particular for the treatment of hematological malignancies. Herein, we report the identification of a new class of potent and highly selective inhibitors of CK1?, ? and ?. Based on their optimal in vitro and in vivo profiles and their exclusive selectivity, MU1250, MU1500 and MU1742 were selected as quality chemical probes for those CK1 isoforms. At proper concentrations, MU1250 and MU1500 allow for specific targeting of CK1? or dual inhibition of CK1?/? in cells. The compound MU1742 also efficiently inhibits CK1? and, to our knowledge, represents the first potent and highly selective inhibitor of this enzyme. In addition, we demonstrate that the central 1H-pyrrolo[2,3-b]pyridine-imidazole pharmacophore can be used as the basis of highly selective inhibitors of other therapeutically relevant protein kinases, e.g. p38?, as exemplified by the compound MU1299.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info